<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496741</url>
  </required_header>
  <id_info>
    <org_study_id>TBA</org_study_id>
    <nct_id>NCT02496741</nct_id>
  </id_info>
  <brief_title>Metformin And Chloroquine in IDH1/2-mutated Solid Tumors</brief_title>
  <acronym>MACIST</acronym>
  <official_title>Phase Ib Study of Metformin and Chloroquine in IDH1/2-mutated Patients With Glioma, Intrahepatic Cholangiocarcinoma or Chondrosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib, open-label, single-center, non-randomized clinical trial will evaluate the&#xD;
      toxicity and efficacy of metformin and chloroquine in isocitrate dehydrogenase 1/2-mutated&#xD;
      (IDH1/2MT) patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioma, intrahepatic cholangiocarcinoma (IHCC) and chondrosarcoma (CS) are aggressive,&#xD;
      malignant cancers with a dismal outcome, the two latter types especially in the&#xD;
      locally-advanced or metastasized setting. This is due to a lack of effective treatment&#xD;
      strategies and highlights the dire need for novel therapies.&#xD;
&#xD;
      A subset of these cancer types are characterized by the presence of mutations in the genes&#xD;
      encoding for isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2). These&#xD;
      mutations occur in 80% of world health organization (WHO) grade II and III glioma and&#xD;
      secondary glioblastoma, 20% of IHCC and 60% of CS and, besides their oncogenic function,&#xD;
      induce metabolic vulnerabilities to IDH1/2MT cancer cells that can be exploited in vitro by&#xD;
      the oral antidiabetic metformin and the oral antimalarial drug chloroquine.&#xD;
&#xD;
      In the present study protocol, the investigators describe a phase Ib single-center clinical&#xD;
      trial in which patients with glioma, IHCC or CS are being screened for IDH1/2MT using the&#xD;
      surrogate marker D-2-hydroxyglutarate (D-2HG), which is exclusively produced in IDH1/2MT&#xD;
      cancers, or DNA sequencing of tumor material. Eligible IDH1/2MT patients are then treated&#xD;
      with a combination of metformin and chloroquine.&#xD;
&#xD;
      The study protocol uses a 3+3 dose-escalation scheme. The primary objective is to determine&#xD;
      the maximum tolerated dose in order to establish a recommended dose for a phase II trial.&#xD;
      Secondary objectives of the study include (1) to investigate the pharmacokinetics of the&#xD;
      combination therapy of metformin plus chloroquine, (2) whether or not IDH1/2MT status can be&#xD;
      determined by magnetic resonance spectroscopy and/or mass spectrometry of the serum, urine&#xD;
      and/or bile or next-generation sequencing of circulating tumor DNA in glioma, IHCC or CS&#xD;
      patients and to (3) investigate the tumor response and D-2HG concentration response to&#xD;
      metformin plus chloroquine in IDH1/2MT cancers.&#xD;
&#xD;
      This study may open a novel treatment avenue for IDH1/2MT glioma, IHCC and CS by&#xD;
      investigating two relatively safe drugs for these highly malignant tumors. In addition, this&#xD;
      study may present novel therapies for other cancers that are regularly affected by IDH1/2MT,&#xD;
      such as acute myeloid leukemia, acute lymphocytic leukemia and T-cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of metformin + chloroquine</measure>
    <time_frame>1 year</time_frame>
    <description>The maximum tolerated dose is the chloroquine plus metformin dose in which no more than 1 in 3 patients (of a 3+3 dose-escalation schedule) observe serious adverse effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of metformin + chloroquine on serum/urine/bile D-2-hydroxyglutarate (D2HG) concentration</measure>
    <time_frame>1 year</time_frame>
    <description>D-2HG concentration will be measured by mass spectrometry (MS) in serum/urine/bile, at the beginning and end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of metformin + chloroquine on intratumoral D2HG concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Intratumoral D-2HG concentration will be measured by magnetic resonance spectroscopy (MRS), at the beginning and end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of metformin + chloroquine on tumor response</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor size will be measured using a MRI/CT scan before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recommended dose of metformin + chloroquine</measure>
    <time_frame>1 year</time_frame>
    <description>The recommended dose is the dose of chloroquine plus metformin is the dose level one step below the maximum tolerated dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Glioma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>Metformin and chloroquine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin will be administered in a 3+3 dose-escalation schedule.&#xD;
Chloroquine will be administered in a fixed dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and chloroquine combination</intervention_name>
    <description>Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.</description>
    <arm_group_label>Metformin and chloroquine combination</arm_group_label>
    <other_name>Aralen</other_name>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presence of a glioma, IHCC or WHO grade ≥ II CS (both newly-diagnosed and&#xD;
             refractory/relapsed tumors)&#xD;
&#xD;
          2. Tumor carries a neomorphic D-2HG generating mutation in IDH1 or IDH2 as determined by&#xD;
             MS of serum and urine (optional: bile), MRS of the tumor or DNA sequencing of&#xD;
             (circulating) tumor material.&#xD;
&#xD;
          3. Measurable lesion according to RECIST 1.1 criteria (see Appendix B) in IHCC and CS&#xD;
             patients and RANO criteria (see Appendix C) in glioma patients.&#xD;
&#xD;
          4. ECOG/WHO performance 0-2 (see Appendix D).&#xD;
&#xD;
          5. Age &gt; 18 years.&#xD;
&#xD;
          6. Adequate renal function (creatinine &lt; 150 μmol/L and/ or a creatinine clearance &gt; 60&#xD;
             ml/ L).&#xD;
&#xD;
          7. Adequate liver function (bilirubin &lt; 1.5 times upper limit of normal, ALAT or ASAT &lt;&#xD;
             5.0 times upper limit of normal in case of liver metastases and &lt; 2.5 the upper limit&#xD;
             of normal in absence of liver metastases).&#xD;
&#xD;
          8. Adequate bone marrow function (WBC &gt; 3.0 x 109/L, platelets &gt; 100 x 109/L).&#xD;
&#xD;
          9. If patient is eligible for resection, surgery is (already) planned at least 4 weeks&#xD;
             away from start study treatment.&#xD;
&#xD;
         10. Mentally, physically, and geographically able to undergo treatment and follow up.&#xD;
&#xD;
         11. Signed informed content obtained prior to treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (positive serum pregnancy test) and lactation.&#xD;
&#xD;
          2. Serious concomitant systemic disorder that would compromise the safety of the patient,&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
          3. Patients who have any severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               -  unstable angina pectoris,&#xD;
&#xD;
               -  symptomatic congestive heart failure,&#xD;
&#xD;
               -  myocardial infarction,&#xD;
&#xD;
               -  cardiac arrhythmias,&#xD;
&#xD;
               -  pulmonary insufficiency,&#xD;
&#xD;
               -  epilepsy (interaction with chloroquine),&#xD;
&#xD;
               -  severe gastrointestinal, neurological or hematological diseases (interaction with&#xD;
                  chloroquine).&#xD;
&#xD;
          4. 6 months prior to randomization:&#xD;
&#xD;
               -  serious uncontrolled cardiac arrhythmia,&#xD;
&#xD;
               -  uncontrolled diabetes as defined by fasting serum glucose &gt;2X ULN,&#xD;
&#xD;
               -  active or uncontrolled severe infection, including malaria,&#xD;
&#xD;
               -  cirrhosis, chronic active hepatitis or chronic persistent hepatitis,&#xD;
&#xD;
               -  severely impaired lung function.&#xD;
&#xD;
          5. Patients that use digoxin, MAO inhibitors, fenylbutazone, oxygenbutazone, gold&#xD;
             preparations or cimetidine (known pharmaco interaction with chloroquine) or loop&#xD;
             diuretics (known pharmaco interaction with metformin) for which no good alternative is&#xD;
             available.&#xD;
&#xD;
          6. Patients that have a known history of alcohol abuse (interaction with metformin).&#xD;
&#xD;
          7. Patients with known glucose-6-phosphate dehydrogenase deficiency, porphyria,&#xD;
             myasthenia gravis or ocular/retinal aberrations (interaction with chloroquine).&#xD;
&#xD;
          8. Patients with a known hypersensitivity to metformin or chloroquine.&#xD;
&#xD;
          9. Patients that are lactose intolerant.&#xD;
&#xD;
         10. Use of metformin or chloroquine in the previous 6 months.&#xD;
&#xD;
         11. Long-term use of chloroquine (&gt;5 years or cumulative dose &gt;300 grams) in the past.&#xD;
&#xD;
         12. Use of other anti-cancer therapy (i.e. surgical resection, chemotherapy, targeted&#xD;
             therapy, radiation therapy, surgery). Palliative therapy is permitted, such as:&#xD;
&#xD;
               -  palliative radiotherapy for symptomatic bone metastases;&#xD;
&#xD;
               -  dexamethasone for symptom relief in patients with glioma and cerebral edema;&#xD;
&#xD;
               -  non-enzyme inducing antiepileptic drugs (with the exception of topiramate) in&#xD;
                  patients with glioma and epileptic seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanneke W Wilmink, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.W. Wilmink</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>isocitrate dehydrogenase 1/2 mutation</keyword>
  <keyword>metformin</keyword>
  <keyword>chloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

